Table 1.
miRs | Targets | Characteristics |
Down-regulated | ||
miR-1 | ET1 | Proliferation[52] |
miRs-7a, -7b, -7c, -7d, -7f-1, -7d | Caspase-3, HMGA2, C-myc, Bcl-xl | Proliferation, apoptosis[2,23,53-58] |
miR-101 | Mcl-1, SOX-9, EZH2, EED, DNMT3A | Proliferation, apoptosis[59-61] |
miRs-122 | Bcl-w, ADAM-1, Wnt-1 | Angiogenesis, apoptosis, Metastasis[45,62-64] |
miR-125a, -125b | MMP11, SIRT7, VEGF-A, LIN28B2, Bcl-2, Mcl-1, Bcl-w | Angiogenesis, apoptosis, metastasis, proliferation[65-70] |
miR-139 | c-Fos, Rho-kinase-2 | Metastasis[30,71] |
miR-145 | IRS1-2, OCT4 | Insulin-like growth factor pathway, Stem-like cells tumorigenicity[31,72] |
miR-195 | CDK6, E2F3, cyclinD1 | Proliferation, apoptosis, tumorigenicity[73,74] |
miR-199a-3p, -199-5p | c-Met, mTOR, PAK4, DDR1, caveolin-2 | Proliferation, autophagy, metastasis[9,75-78] |
miRs-214 | HDGF, catenin | Proliferation, angiogenesis, metastasis[79-81] |
Up-regulated | ||
miR-10a | EphA4, CADM1 | EMT, metastasis[33,82] |
miR-21 | Pten, RhoB, PDCD4 | Drug Resistance, metastasis[49,83-85] |
miR-221 | Bmf, DDIT4, Arnt, CDKN1B/p27, CDKN1C/p57 | Angiogenesis, apoptosis, proliferation[86-89] |
miRs-224 | Yin Yang1/Raf-1 kinase, NFκB pathways, apoptosis inhibitor-5 | Proliferation, apoptosis, metastasis[90-93] |
miRs: MicroRNAs; EMT: Epithelial-mesenchymal transition.